LifeScience Biologics
Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies
- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
September 23, 2026 | News
Tsingke Launches High-Throughput Validation Workflow for AI-Designed Proteins and Antibodies
Tsingke announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed pro...
September 23, 2026 | News
XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Th...
September 23, 2026 | News
Every First Approval in APAC, 2026: The Full List
Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...
September 23, 2026 | Analysis
WuXi XDC Achieves GMP Release for Singapore Bioconjugate Manufacturing Site
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...
September 23, 2026 | News
Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset
Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...
September 23, 2026 | News
Accro Bio Doses First Patient in Phase IIb Trial of RIPK2 Inhibitor AC-101 for Ulcerative Colitis
Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, an...
September 22, 2026 | News
Specialised Therapeutics, Incyte Expand Partnership to Bring Ruxolitinib Cream to Australia
Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: IN...
September 22, 2026 | News
Telix to Merge with ITM in $1.65B Deal, Building Global Radiopharmaceutical Powerhouse
Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities ac...
September 22, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
OGT Expands SureSeq NGS Indexing Capacity to 384 Samples per Run
OGT, a leading global provider of genomic research and diagnostic solutions, announced the expansion of its SureSeq™ Universal NGS Unique Dual Index ...
September 21, 2026 | News
Nona Biosciences Develops AI Language Model for Fully Human Heavy-Chain-Only Antibodies
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, annou...
September 18, 2026 | News
Japan Approves Lundbeck’s Eptinezumab for Migraine Prevention in Adults
Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment ap...
September 18, 2026 | News
Australia’s VVMF Secures TGA GMP Licence for Viral Vector Manufacturing
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises...
September 18, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
